Trung Huynh
Stock Analyst at UBS
(4.60)
# 212
Out of 4,876 analysts
45
Total ratings
64.52%
Success rate
23.35%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trung Huynh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $633 → $560 | $521.00 | +7.49% | 3 | Jun 5, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Buy | $38 → $33 | $5.49 | +501.09% | 2 | May 13, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $44 → $38 | $20.28 | +87.38% | 2 | May 9, 2025 | |
| INSM Insmed | Maintains: Buy | $110 → $109 | $99.49 | +9.56% | 5 | May 9, 2025 | |
| AMGN Amgen | Maintains: Neutral | $319 → $315 | $277.13 | +13.67% | 4 | May 2, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,100 → $1,050 | $775.45 | +35.41% | 8 | May 2, 2025 | |
| PFE Pfizer | Maintains: Neutral | $24 → $25 | $24.19 | +3.35% | 6 | Apr 30, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $60 → $54 | $46.35 | +16.50% | 5 | Apr 11, 2025 | |
| CABA Cabaletta Bio | Maintains: Buy | $10 → $7 | $1.57 | +345.86% | 2 | Apr 1, 2025 | |
| KYTX Kyverna Therapeutics | Initiates: Buy | $13 | $3.28 | +296.34% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $170 → $175 | $152.41 | +14.82% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $126 | $79.10 | +59.29% | 3 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $170 | $182.31 | -6.75% | 1 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $8.87 | - | 1 | Mar 23, 2021 |
Regeneron Pharmaceuticals
Jun 5, 2025
Maintains: Neutral
Price Target: $633 → $560
Current: $521.00
Upside: +7.49%
Jasper Therapeutics
May 13, 2025
Maintains: Buy
Price Target: $38 → $33
Current: $5.49
Upside: +501.09%
Celldex Therapeutics
May 9, 2025
Maintains: Buy
Price Target: $44 → $38
Current: $20.28
Upside: +87.38%
Insmed
May 9, 2025
Maintains: Buy
Price Target: $110 → $109
Current: $99.49
Upside: +9.56%
Amgen
May 2, 2025
Maintains: Neutral
Price Target: $319 → $315
Current: $277.13
Upside: +13.67%
Eli Lilly and Company
May 2, 2025
Maintains: Buy
Price Target: $1,100 → $1,050
Current: $775.45
Upside: +35.41%
Pfizer
Apr 30, 2025
Maintains: Neutral
Price Target: $24 → $25
Current: $24.19
Upside: +3.35%
Bristol-Myers Squibb Company
Apr 11, 2025
Maintains: Neutral
Price Target: $60 → $54
Current: $46.35
Upside: +16.50%
Cabaletta Bio
Apr 1, 2025
Maintains: Buy
Price Target: $10 → $7
Current: $1.57
Upside: +345.86%
Kyverna Therapeutics
Oct 10, 2024
Initiates: Buy
Price Target: $13
Current: $3.28
Upside: +296.34%
Jul 21, 2023
Maintains: Neutral
Price Target: $170 → $175
Current: $152.41
Upside: +14.82%
Mar 7, 2023
Maintains: Outperform
Price Target: $125 → $126
Current: $79.10
Upside: +59.29%
Nov 18, 2022
Initiates: Outperform
Price Target: $170
Current: $182.31
Upside: -6.75%
Mar 23, 2021
Upgrades: Outperform
Price Target: n/a
Current: $8.87
Upside: -